| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The compound is a stable isotope-labeled internal standard used for analytical method development and validation. It does not have a specific biological target but is used to accurately quantify the unlabeled compound in biological samples by mass spectrometry. The labeled analog has identical chemical properties to the unlabeled compound but differs in mass, allowing for its use as an internal standard.
|
|---|---|
| ln Vitro |
In the process of developing new drugs, stable heavy isotopes of carbon, hydrogen, and other elements have been added to pharmacological molecules, mostly as quantitative tracers. Due to its potential effects on medication pharmacokinetics and metabolic properties, deuteration is a matter for worry [1].
In vitro, 6-Chloro-1,3,5-triazine-2,4-diamine-13C3 is used as an internal standard in analytical assays to quantify the unlabeled compound in biological matrices. It is added to samples prior to extraction and analysis by LC-MS or GC-MS. The labeled analog corrects for variability in sample preparation and instrument performance. |
| ln Vivo |
In vivo, 6-Chloro-1,3,5-triazine-2,4-diamine-13C3 is not typically administered to living organisms. It is used as an analytical standard for the quantification of the unlabeled compound in biological samples, such as plasma, urine, or tissue homogenates, obtained from in vivo studies.
|
| Enzyme Assay |
In vitro, 6-Chloro-1,3,5-triazine-2,4-diamine-13C3 is used as an internal standard in analytical method development and validation. A known amount of the labeled compound is spiked into samples, and the samples are extracted and analyzed by LC-MS or GC-MS. The ratio of the labeled to unlabeled compound is used to calculate the concentration of the unlabeled compound. The protocol is used for the quantification of the compound in various biological matrices.
|
| Animal Protocol |
In vivo, 6-Chloro-1,3,5-triazine-2,4-diamine-13C3 is not typically administered to animals. It is used as an analytical standard for the quantification of the unlabeled compound in samples obtained from animal studies. The labeled compound is added to samples prior to analysis by LC-MS or GC-MS.
|
| ADME/Pharmacokinetics |
6-Chloro-1,3,5-triazine-2,4-diamine-13C3 has a molecular weight of 148.53 and the chemical formula ¹³C₃H₄ClN₅. It is a stable isotope-labeled compound. It is supplied as a solid and should be stored in a sealed container in a cool, dry place, protected from light. The compound is for research use only and not for human therapeutic use.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 6-Chloro-1,3,5-triazine-2,4-diamine-13C3 are not extensively documented. As a stable isotope-labeled compound, its toxicity is expected to be similar to that of the unlabeled compound. The compound is for research use only and not for human therapeutic use. It should be handled with appropriate safety precautions, including the use of personal protective equipment.
|
| References | |
| Additional Infomation |
6-Chloro-1,3,5-triazine-2,4-diamine-13C3 is a stable isotope-labeled analog of 6-chloro-1,3,5-triazine-2,4-diamine. It has three ¹³C atoms substituted at the 2, 4, and 6 ring positions. It is used as an internal standard for analytical applications. It has a molecular weight of 148.53. It is supplied as a solid and should be stored in a cool, dry place. It is for research use only.
|
| Molecular Formula |
C3H4N5CL
|
|---|---|
| Molecular Weight |
145.55036
|
| Exact Mass |
148.026
|
| CAS # |
1216850-33-7
|
| PubChem CID |
45038859
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
88.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N[13C]1=N[13C](N)=N[13C](Cl)=N1
|
| InChi Key |
FVFVNNKYKYZTJU-VMIGTVKRSA-N
|
| InChi Code |
InChI=1S/C3H4ClN5/c4-1-7-2(5)9-3(6)8-1/h(H4,5,6,7,8,9)/i1+1,2+1,3+1
|
| Chemical Name |
6-chloro-(2,4,6-13C3)1,3,5-triazine-2,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8705 mL | 34.3525 mL | 68.7049 mL | |
| 5 mM | 1.3741 mL | 6.8705 mL | 13.7410 mL | |
| 10 mM | 0.6870 mL | 3.4352 mL | 6.8705 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
